We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Marrone Bio (MBII), Elephant Vert Ink Distribution Deal
Read MoreHide Full Article
Marrone Bio Innovations, Inc. and Elephant Vert entered into a distribution deal under which the latter will develop and market two of Marrone Bio’s products namely, the biofungicide Reysana and bionematicide Majestene, in Tunisia, Morocco and Algeria.
Bionematicide Majestene protects crops from yield-robbing nematodes and is currently under the process of registration. Biofungicide Reysana is used by growers of peppers, tomatoes, cucurbits and grapes. It contains same ingredients as Marrone Bio’s Regalia Maxx Biofungicide, which is presently marketed and sold in more than 10 countries.
The two pioneering companies in the biological crop protection market have the knowledge and products to bring sustainable solutions, which can improve both quality and yield to farmers in North Africa.
Elephant Vert is a Swiss group that develops and markets biofertilizers, organic amendments, biostimulants and natural biopesticides produced in four production units. According to Elephant Vert, integration of biopesticides into crop protection programs is increasingly important for exporters of vegetables in the region and also benefits all production. The deal opens up potential development opportunities to offer growers in North Africa with a vast range of innovative, efficient and natural solutions.
Marrone Bio has underperformed the industry it belongs to over a year. The company’s shares have lost around 33.8% over this period compared against the industry’s gain of 29%.
Marrone Biorecorded a net loss of $7.4 million or 25 cents per share in second-quarter 2017, compared with a loss of $6.8 million or 28 cents per share a year ago. Loss per share for the quarter was wider than the Zacks Consensus Estimate of a loss of 21 cents.
The company, in second quarter earnings call, announced that it is seeing above industry average growth for its products driven by its portfolio approach to product development and marketing that focuses on addressing unmet market needs and promotes substantial growth opportunities. It is gaining from efforts to grow revenues from existing as well as new products and strategic partnerships in the United States and overseas markets. The company expects its ongoing manufacturing improvement initiatives in research and development to contribute to a meaningful improvement in margins over the long term.
Sociedad Quimica has an expected long-term earnings growth rate of 32.5%.
Koppers has an expected long-term earnings growth rate of 18%.
Kronos has an expected long-term earnings growth rate of 5%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Marrone Bio (MBII), Elephant Vert Ink Distribution Deal
Marrone Bio Innovations, Inc. and Elephant Vert entered into a distribution deal under which the latter will develop and market two of Marrone Bio’s products namely, the biofungicide Reysana and bionematicide Majestene, in Tunisia, Morocco and Algeria.
Bionematicide Majestene protects crops from yield-robbing nematodes and is currently under the process of registration. Biofungicide Reysana is used by growers of peppers, tomatoes, cucurbits and grapes. It contains same ingredients as Marrone Bio’s Regalia Maxx Biofungicide, which is presently marketed and sold in more than 10 countries.
The two pioneering companies in the biological crop protection market have the knowledge and products to bring sustainable solutions, which can improve both quality and yield to farmers in North Africa.
Elephant Vert is a Swiss group that develops and markets biofertilizers, organic amendments, biostimulants and natural biopesticides produced in four production units. According to Elephant Vert, integration of biopesticides into crop protection programs is increasingly important for exporters of vegetables in the region and also benefits all production. The deal opens up potential development opportunities to offer growers in North Africa with a vast range of innovative, efficient and natural solutions.
Marrone Bio has underperformed the industry it belongs to over a year. The company’s shares have lost around 33.8% over this period compared against the industry’s gain of 29%.
Marrone Biorecorded a net loss of $7.4 million or 25 cents per share in second-quarter 2017, compared with a loss of $6.8 million or 28 cents per share a year ago. Loss per share for the quarter was wider than the Zacks Consensus Estimate of a loss of 21 cents.
The company, in second quarter earnings call, announced that it is seeing above industry average growth for its products driven by its portfolio approach to product development and marketing that focuses on addressing unmet market needs and promotes substantial growth opportunities. It is gaining from efforts to grow revenues from existing as well as new products and strategic partnerships in the United States and overseas markets. The company expects its ongoing manufacturing improvement initiatives in research and development to contribute to a meaningful improvement in margins over the long term.
Marrone Bio Innovations, Inc. Price and Consensus
Marrone Bio Innovations, Inc. Price and Consensus | Marrone Bio Innovations, Inc. Quote
Zacks Rank & Stocks to Consider
Marrone Bio currently carries a Zacks Rank #3 (Hold).
Some better-ranked companies in the basic materials space include Sociedad Quimica y Minera S.A. (SQM - Free Report) , Koppers Holdings Inc. (KOP - Free Report) and Kronos Worldwide Inc. (KRO - Free Report) . All three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks Rank #1 stocks here.
Sociedad Quimica has an expected long-term earnings growth rate of 32.5%.
Koppers has an expected long-term earnings growth rate of 18%.
Kronos has an expected long-term earnings growth rate of 5%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>